GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Cash Ratio

VRCDF (Verici Dx) Cash Ratio : 3.56 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Verici Dx's Cash Ratio for the quarter that ended in Jun. 2024 was 3.56.

Verici Dx has a Cash Ratio of 3.56. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Verici Dx's Cash Ratio or its related term are showing as below:

VRCDF' s Cash Ratio Range Over the Past 10 Years
Min: 0.75   Med: 4.35   Max: 25.24
Current: 3.56

During the past 4 years, Verici Dx's highest Cash Ratio was 25.24. The lowest was 0.75. And the median was 4.35.

VRCDF's Cash Ratio is ranked better than
81.65% of 218 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.075 vs VRCDF: 3.56

Verici Dx Cash Ratio Historical Data

The historical data trend for Verici Dx's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Cash Ratio Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash Ratio
26.03 5.73 4.35 0.75

Verici Dx Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash Ratio Get a 7-Day Free Trial 8.39 4.35 2.38 0.75 3.56

Competitive Comparison of Verici Dx's Cash Ratio

For the Diagnostics & Research subindustry, Verici Dx's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verici Dx's Cash Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Verici Dx's Cash Ratio falls into.


;
;

Verici Dx Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Verici Dx's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=2.645/3.508
=0.75

Verici Dx's Cash Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash Ratio (Q: Jun. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=7.015/1.971
=3.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Verici Dx  (OTCPK:VRCDF) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Verici Dx Cash Ratio Related Terms

Thank you for viewing the detailed overview of Verici Dx's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Verici Dx Business Description

Traded in Other Exchanges
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines